Skip to main content
Premium Trial:

Request an Annual Quote

Element Biosciences: Jeff Journey, David Melaugh, Jeff Labbadia

Element Biosciences, a San Diego startup developing next-generation sequencing technologies, has made several appointments to its management team.

Jeff Journey has been named the firm's chief commercial officer. Most recently, he was VP and general manager at Thermo Fisher Scientific, where he oversaw the sample preparation business unit. Prior to that, he held various marketing, sales, service and support, and strategy roles at Thermo Fisher, Johnson & Johnson, and General Electric. He is also a veteran of the US Air Force.

David Melaugh has been appointed as general counsel. He joins Element from Apple, where he was senior director of the worldwide intellectual property litigation team. Prior to that, he was a partner at Morrison & Foerster.

Jeff Labbadia has joined Element as VP of operations. Previously, he spent 22 years at Becton Dickinson, where he held various global operations leadership roles.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.